Mimicking the TLR recognition profile of influenza virus, the intratumoral administration of a TLR3 agonist and a TLR7 agonist has been shown to dramatically reduce tumor progression through increased granzyme B and perforin expression in CD8+ T cells, as well as an increased M1 to M2 macrophage ratio within murine lung tumors [106]. This evidence concerns the gene TLR3 and neoplasm.